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AbstrAct:
A novel way by which the AP-1 factor c-JUN interferes with tumorigenesis has 
recently been elucidated [1]. In a model of murine leukemia, c-JUN prevents the 
epigenetic silencing of the cell cycle kinase CDK6. In the absence of c-JUN, CDK6 
is down-regulated and the 5’region of the gene is methylated. Down-regulation 
of  CDK6  results  in  significantly  delayed  leukemia  formation.  Here  we  show  that 
c-JUN is also involved in protecting the promoter region of the tumor suppressor 
p16INK4a, which is consistently methylated over time in c-JUN deficient cells. In cells 
expressing c-JUN, p16INK4a promoter methylation is a less frequent event. Our study 
unravels a novel mechanism by which the AP-1 factor c-JUN acts as a “bodyguard”, 
and preventing methylation of a distinct set of genes after oncogenic transformation. 
the AP-1 trAnscriPtion fActor 
fAmily – tumor suPPressors And 
Promoters
AP-1 (Activator Protein-1) transcription factors are 
basic leucine-zipper (bZIP) proteins [2-5]. They act as 
dimeric transcription factors composed of members of the 
JUN family (c-JUN, JUNB, JUND), forming homo- or 
heterodimers with members of the FOS, ATF (activating 
transcription factor) and MAF (musculoaponeurotic 
fibrosarcoma) protein family [6-7]. The expression and 
physiological role of the diverse AP-1 complexes is cell 
type- and even differentiation state-dependent [8-10]. 
AP-1 complexes modulate transcription of target genes by 
binding to their TRE or CRE consensus elements [3],[11-
13],[8, 12, 14]. Consequently AP-1 dimers are involved 
in the regulation of various biological processes such as 
proliferation, differentiation and apoptosis [3, 15]. It is 
therefore not surprising that AP-1 factors are involved in 
cellular transformation and tumorigenesis [3, 16-17]. 
c-JUN was first discovered as the homologue of the 
viral oncoprotein v-JUN, which induces avian sarcoma 
[18-19]. Early evidence revealed a cooperation of c-JUN 
with oncogenic RAS in cellular transformation [4, 20-21]. 
On the other hand, some AP-1 family members suppress 
and block tumor development [4, 22-23]. This task has 
been previously been attributed to JUNB, inactivation of 
which provokes the development of myeloproliferative 
disorders [24]. 
Despite the similarity in their primary structure 
and  DNA  binding  specificity,  c-JUN  and  JUNB  differ 
in transcriptional capacity. Both may act either as a 
transcriptional activator or as a repressor depending on 
the promoter context and the heterodimerization partner 
[4, 25-31]. In some tissues c-JUN and JUNB even exert 
antagonistic functions in biological processes such as cell 
proliferation [4, 26-29, 31]. Thus AP-1 is able to modulate 
opposing functions, such as promoting or suppressing 
tumor development.
c-Jun - AccelerAting 
tumorigenesis by driving 
trAnscriPtion 
Since the initial discovery of v-JUN, solid evidence 
has accumulated linking AP-1 members and in particular 
c-JUN to tumor development. Using mouse models, 
c-JUN has been implicated in tumor formation in both 
skin and liver [32-36]. Inhibiting c-JUN activity in basal 
keratinocytes blocks chemically induced papilloma Oncotarget 2011; 2:  422 - 427 423 www.impactjournals.com/oncotarget
figure 1: p16INK4a mrnA levels are down-regulated in c-JunΔ/Δ p185BCR-ABL-transformed cell lines. A) p16INK4a mRNA levels 
of c-JunΔ/Δ and c-Junfl/fl cells 2, 4, 6 and 8 weeks after p185BCR-ABL transformation were analyzed by q-PCR. The fold change compared to 
c-JunΔ/Δ 2 weeks p16INK4a mRNA level is shown. Results were normalized by comparison to their Gapdh mRNA expression. B) upper 
panel: Methylation-specific PCR analysis of p16INK4a in stable c-Junfl/fl and c-JunΔ/Δ cell lines as detected by MSP analysis. A visible PCR 
product indicates the presence of methylated alleles. Abbreviations: H.M., bone marrow of a healthy mouse; +Ctrl (control for methylated 
samples); -Ctrl (control for unmethylated samples). Lower panel: Graphical overview of the CpG island associated with p16INK4a (Cdkn2a) 
(ENSMUSG00000044303). The following genomic region is shown: NCBIM37:4:88927717:88928797:-1. Vertical bars (orange) indicate 
the location of CpG dinucleotides, horizontal arrows indicate MSP primer binding sites and vertical arrows indicate AP1 transcription 
factor binding sites predicted using the transcription factor binding profile database JASPAR (http://jaspar.genereg.net/). C) Immunoblot 
for c-JUN and p16INK4a of c-JunΔ/Δ and c-Junfl/fl cells after 12, 24, 36 and 48 hours of Aza-dC treatment. β-Actin served as loading control. 
One representative set of data is depicted.
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formation because of the lack of expression of the AP-1 
target  genes  [37].  In  hepatocellular  carcinoma,  gene 
deletion of c-Jun after tumor onset leads to a significant 
reduction in tumor size. This effect has been explained 
as resulting from increased apoptosis induced by c-JUN 
dependent suppression of the pro-apoptotic gene p53 [36, 
38]. Upon loss of c-JUN, p53 mediated apoptosis kicks in 
and leads to a significant reduction of tumor burden [36]. 
Similarly, murine embryonic fibroblasts (MEFs) lacking 
c-JUN show severe cell cycle abnormalities with a block 
in the G1-phase of the cell cycle [39]. These fibroblasts 
demonstrate  increased  expression  of  the  pro-apoptotic 
gene p53 and its target gene, the cell cycle inhibitor p21CIP 
[38]. As in hepatocytes, c-JUN negatively regulates the 
transcription of p53 in MEFs by direct binding to the 
promoter region of p53. The concomitant deletion of p53 
rescues the apoptotic and proliferative disadvantage [38, 
40]. 
Besides c-JUN’s “survival” function in interfering 
with p53 induced apoptosis, c-JUN has been shown 
to  drive  cell  proliferation.  One  defined  “hallmark”  of 
tumor formation is a deregulated cell cycle and c-JUN’s 
ability to effect this represents a further way in which 
the protein contributes to tumorigenesis. A direct pro-
proliferative function of c-JUN is mediated through the 
regulation of CyclinD1 [38-39, 41]. c-JUN is able to bind 
to the CyclinD1 promoter and induces transcription in a 
phosphorylation-dependent  manner,  as  the  exchanges 
of critical serine residues to alanine (JunAA/AA) decrease 
CyclinD1 transcription [30]. Both CyclinD1 and c-JUN 
are overexpressed in a broad range of human cancer and 
both molecules are considered proto-oncogenes [10, 42-
45]. Another cell-cycle regulator under the control of AP-1 
members is the cell cycle inhibitor p16INK4a. Several AP-1 
binding sites within the p16INK4a promoter enable AP-1 to 
control expression of the gene. JUNB has been defined as 
a positive regulator and induces p16INK4a expression [27, 
46].
A novel mechAnism for c-Jun
An additional cell cycle component regulated by 
c-JUN is the G1-cell cycle kinase CDK6. CDK6 is most 
closely related to CDK4 and is required to allow cells 
to progress through the G1-phase of the cell cycle after 
binding  to  D-type  Cyclins  [47-50].  CDK6  and  CDK4 
generally have overlapping and redundant functions but 
CDK6, unlike CDK4, has been recently recognized to be 
a regulator of differentiation [51-54]. 
When we analyzed pro B-cells transformed by the 
oncoprotein BCR-ABL we found a peculiar regulation 
of  CDK6  downstream  of  c-JUN  [1].  Over  time  BCR-
ABL-transformed cells lacking c-JUN had lower levels of 
CDK6 protein as well as mRNA. The decline in protein 
expression  was  independent  of  c-JUN  phosphorylation 
as  CDK6  was  stably  expressed  in  BCR-ABL+  JunAA/
AA cells, in which the mutant JUN protein can no longer 
be phosphorylated. Interestingly, the reduction of CDK6 
was accompanied by methylation of the 5’region of Cdk6 
and could be reversed by treatment of the cells with the 
DNA methyltransferase (DNMT) inhibitor 5-aza-2’-
deoxycytidine  (Aza-dC).  Two  AP-1  binding  sites  are 
found in the vicinity of the methylated region. This led 
us to suggest that c-JUN exerts a “bodyguard” function, 
being required to prevent the Cdk6 promoter from being 
silenced. Only in the absence of c-JUN can methylation 
of the 5’region of Cdk6 take place and CDK6 expression 
be silenced. This effect is restricted to transformed cells 
and induced by the oncogenic event, as primary non-
transformed  lymphoid  cells  display  unaltered  CDK6 
scheme 1: A transcriptional complex, including c-Jun, binds to dnA and methylation is inhibited. In the absence of 
c-JUN, DNMTs can bind and methylate gene promoter regionOncotarget 2011; 2:  422 - 427 425 www.impactjournals.com/oncotarget
expression levels. It is attractive to speculate that c-Jun 
may also shape age-related DNA methylation by acting 
as a “bodyguard” to protect distinct DNA regions during 
aging [55-57]. 
Altering CDK6 expression has major consequences 
for leukemia and lymphoma development. Using Cdk6-
/-  animals  we  detected  a  significant  delay  in  tumor 
formation. Thus, it is safe to conclude that by preventing 
the silencing of CDK6 c-JUN accelerates and promotes 
leukemogenesis. In the same murine model of BCR-
ABL+  leukemia,  JUNB  exerts  an  antagonistic  role.  In 
accordance with its role as tumor suppressor, the enforced 
expression of JUNB suppresses tumor formation and the 
lack of JUNB lead to a highly aggressive and rapidly 
progressing disease. Again we found a role for CDK6; the 
lack of JUNB was accompanied by high CDK6 expression 
levels. How precisely JUNB interferes with the regulation 
of CDK6 remains to be determined [46].
CDK6 is not the only cell cycle regulator under the 
control of c-JUN. We found a consistent downregulation 
of the tumor suppressor and cell cycle inhibitor p16INK4a in 
c-JUN deficient BCR-ABL+ cells [1]. The levels of both 
the protein and the mRNA (Figure 1A) of p16INK4a decline 
with time after BCR-ABL-transformation, as verified by 
micro-array experiments [1]. 
As shown for Cdk6, we found promoter methylation 
of p16INK4a in all stable BCR-ABL+ c-JunΔ/Δ cell lines. In 
the case of wild type, only half the cell lines displayed 
methylated CpG islands (Figure 1B). Treatment of the 
cells with Aza-dC reverted the reduction of p16INK4a in 
cells lacking c-JUN (Figure 1C). Interestingly, no changes 
could be induced by treating wild type cells with this 
agent, indicating that additional regulatory mechanisms 
had shut off p16INK4a in the tumor cell lines. As is the case 
for Cdk6, the promoter region of the p16INK4a gene contains 
a number of AP1-binding sites, which is consistent with 
our model, that c-JUN is required to protect the p16INK4a 
promoter from being silenced by methylation. 
conclusion
c-JUN is a common regulator of cell cycle 
components that has been described to have a direct 
role in regulating the transcription of p53 and CyclinD1. 
Based on our studies we postulate a novel mechanism 
for how c-JUN accelerates leukemogenesis and regulates 
genes required for cell cycle progression in tumor cells. 
We propose that binding of c-JUN to the promoter region 
exerts a protective function and prevents methylation and 
silencing of the genes. This function of c-JUN has recently 
been demonstrated for the cell cycle kinase CDK6. In the 
absence of c-JUN, CDK6 is downregulated accompanied 
by methylation of the 5’region. We now show that the 
same mechanism occurs at the promoter region of the 
cell cycle inhibitor and tumor suppressor p16INK4a. Our 
results indicate a novel mechanism by which AP-1 factors 
modulate tumor formation.
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